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Randall Jenkins
Abstract
Phthalates are a ubiquitous group of industrial compounds used as industrial 
solvents and as additives to plastics to make products softer avnd more flexible. 
Phthalates are found in a variety of products including medical devices, personal 
care products, flooring, and food packaging. Infants in the neonatal intensive care 
unit are exposed to phthalates both in the building materials, but more importantly 
in the medical supplies and devices. Toxicity from phthalates has been of concern 
to researchers for many decades. Toxicity concerns to neonates includes male 
reproductive toxicity, hepatotoxicity, cardiotoxicity (including hypertension), 
neurotoxicity, and neurodevelopmental abnormalities. Limited recommendations 
have been given for reducing phthalate exposures to premature infants. These 
include avoiding infusing lipids or blood products through intravenous tubing 
containing phthalates. Storage of blood in containers made with phthalates has been 
a strong recommendation and has largely been accomplished. A comprehensive 
plan for phthalate reduction has heretofore been missing. This chapter has the goal 
of identifying the problem of phthalate exposure in premature infants, with some 
practical solutions that can be done today, as well as suggestions for manufacturers 
to complete the work.
Keywords: phthalates, neonate, hypertension, toxicity, di-2-ethylhexyl phthalate 
(DEHP)
1. Introduction
After the year 2000, we began observing a pattern of hypertension in premature 
infants [1]. In 2019, we reported on an evaluation of 97 premature infants revealing 
common features including near-universal low plasma renin activity, transient time 
course, and a good clinical response to treatment with spironolactone. Meanwhile, 
Trasande had recently shown an association with phthalate compounds and ele-
vated blood pressure in children [2]. A few years earlier, Zhao proposed a possible 
mechanism for elevated blood pressure related to phthalates. Zhao documented in 
human microsomes how monoester phthalate metabolites cause sodium retention 
via inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) 
[3]. This is the same enzyme responsible for licorice-related hypertension and the 
syndrome of apparent mineralocorticoid excess [4].
When considered together, these concepts led to a prospective study to evaluate 
the hypothesis that phthalates increase blood pressure in premature infants, and 
may cause the heretofore unexplained hypertension in this population [5]. The 
study showed phthalate exposure was associated with increased blood pressure and 
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hypertension in premature infants. Evidence was presented for activation of the 
mineralocorticoid receptor among hypertensive premature infants [5]. This experi-
ence raised our awareness of other potential toxic effects of phthalates in premature 
infants, and has spurred a more comprehensive examination of phthalates’ effect on 
premature infants.
Phthalates are a ubiquitous group of industrial compounds related to phthalic 
acid [6]. These compounds are used as industrial solvents and additives to make 
plastic softer and more flexible. Phthalates are found in a variety of products 
including medical devices, personal care products, flooring, and food packaging 
[7]. Infants in the neonatal intensive care unit are exposed to phthalates in the 
room’s construction materials, but more importantly in the department’s medical 
supplies and devices [7, 8].
Toxicity from phthalates has been of concern to researchers since the 1970s. 
Research showing male reproductive toxicity in animals raised alarms for human 
exposures, especially as phthalates are known to be endocrine disruptors [9, 10]. 
Although steroidogenesis in rodents is quite different from that of humans, con-
cerns have been validated for various endocrine effects of phthalates on developing 
humans [10]. Toxicity concerns to neonates include hepatotoxicity, hypertension, 
neurotoxicity, and neurodevelopmental abnormalities [7].
Limited actions have been recommended for reducing phthalate exposures 
to premature infants [11, 12]. These include avoiding infusions of lipids or blood 
products through phthalate-containing intravenous tubing, as well as avoiding 
blood storage containers which are comprised with phthalates [11–13]. Of these 
recommendations, only the proper storage of blood has been broadly adopted 
[13]. A comprehensive plan for phthalate reduction has heretofore been missing. 
This chapter’s goal is to identify the problem of neonatal phthalate exposures and 
provide a blueprint for phthalate exposure reductions that can be achieved immedi-
ately, as well as suggest how manufacturers can further this work for the benefit of 
premature infants.
2. Phthalates: what are they?
Phthalates are a group of low-cost compounds which are used in the industrial 
production of commercial products [6, 7] In 2015, almost 8 million metric tons 
were produced [14]. Phthalates are used as solvents, and as a softening agent 
(plasticizer) in polyvinyl chloride (PVC). Phthalates are not covalently bound to 
the plastic and act by preventing the full polymerization of the PVC, thus impart-
ing elasticity and flexibility to the plastic [15]. Phthalates are used in the production 
of vinyl flooring, wall coverings, food packaging, personal care products, toys, 
upholstery, fragrances, pharmaceuticals, fragrances, baby-care products, and 
medical supplies and devices [6, 7, 16–20]. PVC products may be comprised of up to 
50% phthalates [16].
Di-2-ethylyhexyl phthalate (DEHP) is the most common phthalate used in the 
medical setting. DEHP is the only phthalate approved by the US Food and Drug 
Administration (FDA) for use in medical products. In the EU, where DEHP has 
been banned, alternative phthalate plasticizers are used, including di (isonyl)
cyclohexane-1,2-dicarboxylate (DINCH), tris (2-ethylhexyl) trimellitate (TOTM), 
di (2-ethylhexyl) terephthalate (DEHT), di-(2-ethylhexyl) adipate (DEHA), acetyl 
tri-n-butyl citrate (ATBC), di-isodecyl phthalate (DiDP), di-isonlyl phthalate 
(DINP), and di (2-prophylheptyl) phthalate (DPHP) [21, 22]. DINCH and ATBC 
are both used for blood product storage as these prevent excessive hemolysis during 
storage [23]. Toxicity data is limited on many of these alternatives, making safety 
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determination difficult to ascertain [21, 24]. This chapter will focus primarily on 
DEHP, as it is the most-studied and most prevalent plasticizer in the world [7].
Humans are exposed to phthalates via food (from packaging), dermal absorp-
tion, and air inhalation [7, 15–20]. In the hospital setting, infants receiving 
respiratory therapy are exposed to phthalates through three primary means; 
from indwelling catheters and tubes, from intravenous fluid; and from the 
room’s air [5, 7, 8, 11, 12, 16].
3. Metabolism and excretion of phthalates
Phthalates are quickly metabolized and excreted in urine [19, 24], making urine 
an ideal medium for monitoring phthalate exposures [7, 19, 24]. DEHP is metabo-
lized to MEHP via pancreatic and other lipases. MEHP is the primary metabolite 
in urine along with two secondary metabolites, MEOHP and MEHHP. Further 
metabolic pathways are detailed by Koch et al. [19, 24], but include glucuronidation 
and excretion, leaving little tissue accumulation [20]. In adults, 44.2% of a DEHP 
exposure is excreted in 24 hours via these three metabolites [25]. This knowledge 
has allowed quantitative predictions of DEHP exposure based on urine metabolite 
measurements using an equation by David [26] as modified by Koch [24, 25]. It is 
not known how these predictions might vary when considering premature infants. 
Understanding the metabolic pathways is important, as there is ample evidence that 
the metabolites of DEHP are more toxic than the original compound [3, 8, 16].
Metabolism of DEHP is likely to be different in premature infants as com-
pared to adults or older children [9]. Pancreatic enzymes are not full mature until 
6–12 months of age [27, 28]. Glucuronidation activity is also not mature until three 
months of age, which may increase the half-life of MEHP in these infants [29].
Monitoring studies have found detectable levels of phthalates in almost all 
populations on the planet, with levels in children typically several times higher than 
in adults [7]. Zhang et al. showed that the median concentration of DEHP metabo-
lites in children is 38.5 mcg/Liter, and 43.3 in adults [30]. This concentration can 
be double in pregnant women [31]. Premature infants, by virtue of their small size, 
and exposure to invasive medical products may have exposures that are more than 
4,000 times the levels considered safe for reproductive toxicity [12]. Also, of great 
concern to premature infants, phthalates have been shown to cross the placenta, and 
have been measured in human amniotic fluid [32, 33].
4. Adverse effects from phthalates
4.1 Early animal studies on cancer and reproductive risks of DEHP exposures
Postnatal phthalate exposures have raised concerns of potential carcinogenic, 
mutagenic, reproductive, hepatic, and cardiotoxic effects [34–37]. Some of the first 
concerns raised from animal studies included carcinogenic risks. Rodents treated 
with DEHP had increased risk of hepatocellular carcinoma [38]. This risk prompted 
the EPA to classify DEHP as a possible human carcinogen [7]. As these studies were 
performed only in animals, it remains unclear as to the actual human carcinogenic 
risk from DEHP.
Other early animal (rodent) studies have shown that phthalate exposure can 
result in abnormal anogenital distance, pathologic changes in rodent testes, hypo-
spadias and cryptorchidism, and reduced circulating testosterone [39]. Reviews 
of phthalate anti-androgenic reproductive toxicity are available [40–42]. Prenatal 
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exposures to phthalates have been associated with endocrine disruption, and have 
been reviewed by Martinez-Arguelles [10]. As steroidogenesis is different between 
rodents and humans, it remains unclear the magnitude of reproductive toxicity 
phthalates cause in humans.
4.2 Cardiovascular toxicity
Intrauterine DEHP exposure has been associated with cardiac malformations 
and alteration of key cardiac transcription factors in animals [43]. Both Wang and 
Snijder separately reported an increased risk of cardiac defects with increased 
parental exposure of phthalates [44, 45]. DEHP has been shown to inhibit gap 
junction intercellular communication in lung fibroblasts [46], sertoli cells [47], and 
cardiomyocytes [48].
DEHP exposure can decreased cardiac contractility in animals. Chick myositis 
exposed to 4 mg/ml of DEHP stopped beating after 30 minutes, and 97–98% of 
cardiomyocytes died after 24 hours of exposure [49]. DEHP exposures 6 times 
this level can be seen in children on ECMO [50]. Similar findings occurred when 
rat hearts were perfused with blood from blood bags containing DEHP [51]. 
Lastly, embryonic human cardiomyosites showed a decline in spontaneous beat-
ing after exposure to DEHP at 50 mg/ml [52]. A more complete summary of the 
effects of DEHP on electrophysiology and contractility was published in 2020 by 
Ramadan et al. [53].
In 2013, Trasande reported that DEHP exposures were associated with increased 
blood pressure in children [2]. Other reports showed the same in adults [54, 55]. 
Just a few years earlier, Zhao et al. provided a possible explanation how DEHP 
might raise blood pressure [3]. He demonstrated in human microsomes that MEHP 
(a DEHP metabolite) inhibits 11β-HSD2, the enzyme that converts cortisol into 
cortisone, the less potent mineralocorticoid. Excess cortisol activates the mineralo-
corticoid receptor, resulting in sodium retention. This is the mechanism of action 
for licorice-related hypertension, or the syndrome of apparent mineralocorticoid 
excess [4].
Our group reported that DEHP exposure in premature infants is associated with 
increased blood pressure and hypertension [5]. In a cohort of premature infants, 
we showed evidence of inhibition of 11B-HSD2 via changes in measurement of 
urinary cortisol/cortisone ratio which is a marker for 11β-HSD2. We also showed 
that markers of sodium channel activity were increased in infants exposed to DEHP. 
Hypertension in these neonates responded to treatment with spironolactone, and 
resolved over 10–20 weeks [5].
A subsequent study showed hypertension virtually disappeared when DEHP-
containing intravenous fluid (for both mothers and infants) was removed for a 
two-year period [56]. Subsequently the DEHP-containing IV fluid returned and the 
hypertension returned to the same level prior to removal. There remain two large 
unknowns: first, it is unknown as to what is the crucial time period during which 
DEHP exposure might result in hypertension; second, it is unknown if prenatal 
DEHP exposure may have an epigenetic effect necessary for, or potentiating the 
development of subsequent hypertension in premature infants.
4.3 Metabolic and genetic toxicity
Phthalates can upregulate gene expression [57, 58]. One such gene which has 
been reported to upregulate after DEHP exposure is peroxisome proliferator-
activated receptor alpha (as well as its cofactor) to increase utilization of fatty acid 
substrates in cardiomyocytes [57]. Aronson reported increased lactate levels and 
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lower ATP levels following DEHP exposure [51]. Martinelli suggested that DEHP 
exposure to animal skeletal muscle could disrupt glucose metabolism [58]. Amara 
showed that DEHP exposed mice have altered lipid profiles with higher triglycer-
ides, cholesterol and high and low lipoproteins [59]. Human children aged 6–18 
exposed to the metabolite MEHP had increased obesity, triglycerides, and increased 
blood pressure [60].
4.4 Immunity and oxidative stress effects
MEHP (the principal metabolite of DEHP), has been found in neonates to 
inhibit neutrophil apoptosis and chemotaxis [61]. Synthesis of integrin CD11b is 
doubled by exposure to DEHP at concentrations of 0.1–0.3 mg/L [62]. This integrin 
is involved in leukocyte adhesion and can thereby increase inflammation. Exposure 
of human neutrophils to MEHP can increase H2O2 content and inhibit apoptosis 
and chemotaxis [61]. Exposure of mice to inhaled MEHP results in a significant 
increase in lymphocytes, neutrophils and eosinophils in broncho-alveolar lavage 
fluid [63]. DEHP exposure has been linked to increased oxidative stress, both as 
indicated directly above, and also by increased malondialdehyde levels in infants 
and children receiving lipids and hyperalimentation fluid containing DEHP [64].
4.5 Pulmonary toxicity
Rat pups exposed to maternal DEHP during the final week of gestation showed 
marked enlargement in terminal airspaces, and a reduction in the number of 
airspaces, along with decreased surface area for gas exchange [65]. These findings 
closely resembled those seen with bronchopulmonary dysplasia. A similar study in 
rat pups also showed pathologic changes similar to BPD when analyzed during the 
postnatal period [66].
4.6 Hepatic toxicity
Rabbits were exposed to similar lipid infusions through IV tubing with and 
without DEHP. The non-DEHP tubing was made of polyethylene. After a three-
week infusion of these lipids, only the DEHP exposed rabbits showed liver fibrosis, 
cell necrosis, and other features of oxidative stress. The conclusion was that DEHP 
was responsible for hyperalimentation-related cholestasis [67]. Von Rettberg et 
al. performed a similar study in human premature infants [68]. One group of 30 
neonates receiving parenteral nutrition via DEHP-plasticized PVC tubing for three 
years. A second group of 46 neonates receiving parenteral nutrition via PVC-free 
tubing for three years. When comparing incidence of TPN-associated cholestasis 
they found that the incidence of cholestasis decreased from 50–13% after the 
change to PVC-free tubing. This translated to an increased risk of cholestasis with 
use of DEHP-plasticized PVC tubing by a factor of 5.6 [68].
4.7 Neurologic toxicity
Gestational and postnatal DEHP exposure has adverse effects on rat brain 
development and function [69]. Rat pups were exposed to intraperitoneal infusion 
of DEHP (10 mg/kg/day x 7 days) during the crucial time of hippocampal develop-
ment. These pups at day 26 showed decreased innervation and neuronal density in 
specific hippocampal regions in males but not females exposed to the DEHP [70] 
In a similar study, the same abnormal hippocampal development was also seen 
only in males exposed to DEHP [71]. DEHP exposure in utero caused metabolic 
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disturbances of the lipid metabolome of the fetal rat brain, causing anomalous 
brain growth [69]. Other animal studies on DEHP and brain development are 
detailed in a review by Rowdhwal et al. [72].
Prenatal exposure to phthalates has been associated with poorer infant execu-
tive function, attention, and motor reflexes [73, 74]. In-utero DEHP exposure has 
also been associated with childhood impairments of cognitive dysfunction, motor 
function, executive function, as well as hyperactivity [75, 76], and autism spectrum 
[77] in term infants [75, 78]. Another study looked at IQ in 7-year-old children as 
a function of phthalate levels of pregnant mothers in their third trimester. IQ was 
6–7 points lower in the mothers exposed to the highest levels of two phthalates, 
DnBP, and DiBP. Stroupstrup has begun a large study to study DEHP exposure 
in premature infants [79], given the similarity of the above abnormalities, and 
similar “preterm behavioral phenotypes” seen in premature infants as described by 
Montagna and Nosarti [80].
5. Exposures of DEHP in premature infants
Children and adults are exposed to phthalates primarily through ingestion of 
food, inhalation of dust, chewing or sucking on objects, inhalation of vapor, skin 
absorption from personal care products [7, 9] . In contrast, premature infants are 
exposed both trans-placentally before birth, and through exposure to medical 
devices after birth [5]. There are little data on the magnitude of trans-placenta 
transfer of phthalates. Data on postnatal phthalate exposure is much more robust, 
and dates back almost 50 years to 1973 and 1974 when DEHP was shown to be pres-
ent in blood plasma and cryoprecipitate products [81, 82]. Of importance, DEHP is 
the only FDA-approved phthalate allowed in medical products for use in the USA.
5.1 Early determinations of DEHP exposures in premature infants (1980–2003)
In the late 1980s, Schneider et al. was one of the first to report high levels of 
DEHP exposure in ECMO circuits [83]. Also during this time, Barry et al. showed 
presence of DEHP in cardiac bypass circuits [84]. Roth et al. and Latini et al. also 
presented data showing presence of DEHP in respiratory tubing and endotracheal 
tubes in mechanically ventilated preterm infants [85, 86]. A few years later, Latini 
and Chellini showed that PVC endotracheal tubes were about 23% DEHP by weight, 
and that almost half of the DEHP can leach into the infant over several days time 
[87, 88]. Chellini et al. estimated the exposure to a 2 kg infant could be a mean of 
49 mg/kg over several days-time [87].
In 2000, Loff et al. were the first to demonstrate that PVC IV infusion lines 
expose infants to large amounts of DEHP [89]. Several years later, Loff showed that 
when lipids were administered through PVC IV lines (containing DEHP) could 
leach about 6.5 mg/kg/day for a 24 hour lipid infusion [11]. Loff advised that PVC 
IV lines containing DEHP should be abandoned – this has not happened. Similarly, 
Kambia et al. demonstrated large DEHP exposure in patients receiving parenteral 
(IV) nutrition [90].
5.2 Quantitative DEHP exposures in the NICU
In 2004, Antonio Calafat et al. were the first to report quantitative evidence 
that premature infants receiving intensive medical treatment are actually exposed 
to higher concentrations of DEHP than the general population [8]. Calafat’s group 
examined 33 urine samples from 6 premature infants between 4 and 92 days of age. 
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Most of the samples were obtained after the first month. Samples were analyzed 
for MEHP as well as the two principal oxidative metabolites, MEOHP and MEHHP. 
During the hospital stay, these infants were exposed to a variety of devices, but 
the data was not robust enough to show the effect of particular interventions or 
devices. DEHP metabolites were measureable in all 33 samples, demonstrating the 
ubiquity of DEHP exposure in this population. Metabolite levels varied widely from 
sample-to-sample—up to 100-fold. The median concentration of MEHP in these 6 
premature infants was 129 ng/mL, which is about 26-fold higher that the US median 
of 3.43 ng/mL seen in children aged 6–11 years of age [91, 92]. Similar findings were 
seen for MEOHP and MEHHP levels in premature infants as compared with the US 
median for children, although these two oxidative metabolites are typically about 
10-fold higher than that for MEHP across all samples [8].
A follow-up study was done soon thereafter by the same group, this time 
dividing 54 neonates (from two institutions) into low, medium, and high DEHP 
exposure [93]. The “low” DEHP exposure group was comprised of infants receiv-
ing bottle or gavage feeds with no other interventions. The “medium” group was 
comprised of infants who either had indwelling feeding tubes, parenteral nutrition, 
or were on continuous positive airway pressure devices. The “high” DEHP exposure 
group was comprised of infants intubated and on a mechanical ventilator while also 
receiving parenteral nutrition. As expected, infants in the “low” category showed 
urine DEHP metabolite levels only slightly more than the US averages noted above. 
Exposures as measured in the median group were about 7-fold higher, with expo-
sures in the “high” group another 3-fold higher than seen in the “medium” group. 
Interestingly, urine metabolite levels varied greatly, with DEHP metabolite levels in 
one NICU being about 4-fold that of the other. This was speculated to be due to a 
difference in the frequency two DEHP-containing devices used: PVC endotracheal 
tubes and PVC umbilical catheters [93].
A year later, this group examined two other phthalates, dibutyl phthalate and 
monobenzyl phthalate, both used in personal care and construction products [94]. 
Metabolites of these two phthalates were detected in all 54 of the samples from the 
prior study, but these levels did not vary by gender, institution, or level of inten-
siveness of care. This information suggests that the premature infants are not only 
exposed to phthalates through medical products, but also from other parts of their 
environment, whether it be in the air, in their feedings, or in materials they contact.
Using a different approach, Mallow used data from the above-reported DEHP 
exposures in the NICU to estimate a typical daily DEHP exposure for a prototypical 
infant receiving blood, intravenous nutrition (including lipid infusions), mechani-
cal ventilation, and a feeding tube [12]. Mallow estimated that a 2-Kg infant would 
receive 16.3 mg/day of DEHP while on all of this intervention.
5.3 A recent comprehensive quantitation of DEHP exposures in an NICU
Over more than twenty years since many of the potentially toxic exposures of 
DEHP have been reported, manufacturers have come out with some alternatives to 
DEHP, which include use of other polymers aside from PVC, as well as alternative 
phthalate plasticizers [95]. Braun, USA, markets DEHP-free intravenous fluid in the 
USA. We have observed that feeding tubes, IV administration tubing, and endotra-
cheal tubes are readily available in DEHP-free material, although DEHP-containing 
products are still marketed. The only medical devices for which DEHP-free materi-
als have not been observed are bags of sterile water for respiratory humidification, 
suction devices, urine collection bags, and most tubing for respiratory devices [5].
This last year, our group sought to examine the current state of DEHP exposure 
in a single large Northwestern US NICU [96]. This was accomplished both by 
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direct and indirect measurement of DEHP exposure in premature infants. For all 
intravenous products, including IV fluid, hyperalimentation fluid, lipid emulsions, 
and tubing sets, we directly measured the amount of DEHP leaching into IV fluid 
collected in a glass container at the “patient” end of sham IV circuits. Indirect mea-
surement of DEHP exposure was based on urine metabolites collected in 12 prema-
ture infants receiving one specific respiratory therapy for two days or more (mean 
of 13 days). Koch’s method was used to predict 24-hour DEHP intake based on a 
formula estimating 44.2% of DEHP intake is excreted in the three main metabolites 
(MEHP, MEHHP, and MEOHP) [24].
These results (Table 1) showed that IV DEHP exposures were zero when 
DEHP-free IV fluid was tested using DEHP-free tubing. Similarly, lipid emulsions 
(other than a fish-oil product) when administered through DEHP-free tubing 
DEHP exposure was measured at zero (below level of detection). Use of intrave-
nous fluid gave varying DEHP exposures, magnified many-fold when administered 
through DEHP-positive tubing. Most striking was the enormous exposure related 
to hyperalimentation and lipid infusions when administered through DEHP tubing. 
In this case, DEHP daily exposures were in the range of 12 mg per day (range of 
3.4–45 mg/day).
DEHP exposures from respiratory devices, including patients receiving no known 
DEHP exposures, are shown in Table 2. A wide range of exposures was observed. 
Most exposures were low, and not statistically different from “baseline” patients 
in room air who were not receiving any intravenous fluid (or any other known or 
suspected DEHP exposure). The “baseline” patients had a median DEHP exposure of 
25.5 mcg per day. The baseline exposure was presumed to be related to environmental 
(likely air vapor) in the NICU. Among these “low-level” exposures, the DEHP expo-
sures from mechanical ventilators appeared the highest at 61.4 mcg/day. Given the 
small numbers of tests, this was not statistically different from the baseline patients.
DEHP exposure related to continuous positive airway pressure (CPAP), specifi-
cally the bubble CPAP system, was remarkably higher than any other device tested. 
The median daily DEHP exposure was 7843 mcg per day, which is about 300-fold 
that seen in baseline patients. There was strong evidence that the bubble CPAP 
exposures were not spurious, given no significant variation was seen among six 
samples obtained in 4 patients, and tested at two unrelated laboratories. This report 
did not specifically test CPAP systems separate from bubble CPAP, but noted a 2019 
study where two mask (non-bubble) CPAP patients had urine metabolite levels 
below the level of detection [5]. Lastly, no data is available for DEHP exposures 
from oscillator, jet ventilator, or non-invasive ventilation systems.
This study estimated DEHP exposure in 14 premature infants based on a chart 
review of all recorded IV and respiratory DEHP exposures. The value from the 
tables above were used to tabulate the daily DEHP exposure for each patient. 
Table 3 shows the mean exposures for these 14 infants for each fluid or device. 
The mean DEHP exposure from IV fluid including hyperalimentation and lipid 
infusions was 4,039 mcg over the course of the NICU stay. The mean respiratory 
DEHP exposure was much higher than the intravenous exposures at 221,369, 
with 97% of that exposure attributable to bubble CPAP therapy. The total DEHP 
exposure for the NICU stay was a mean of 182,369 mcg/kg.
5.4 Determination of safe levels of DEHP exposure
Determination of safe levels of DEHP exposure has proved to be a complex and 
daunting task. One of the difficulties is that extrapolation of animal data to humans 
can be misleading. Animal studies may be done with different levels of exposure, 



































Intravenous Product Median IQ Range Range Median IQ Range Range Median IQ Range Range
From Container DEHP-Negative IV Set DEHP-Positive IV Set
DEHP-negative IVF 0.0 0.0 0–0.2 0.0 0.0 0–0 5.2b 12.1 2.4–15.0
DEPH-unlabeled IVF 27.0 —a 26–40 2.4 1.4 1.4–3.2 11.0b 16.2 2.3–26.0
DEHP-positive IVF 560.0 —a 560–620 32.0 24.1 7.6–40 15.0 24.8 4.4–38.0
HA fluid 5.1 —a 3.4–13.0 6.7 13.1 0–16 500.0b 1430 420–2300
Mixed lipid emulsion 1.9 4.4 0–5.9 0.0 0.0 0–0 9300b 4300 6100–13,000
Fish oil lipid emulsion 8.3 10.8 0–15 92.0 62.6 74–170 4000b 3350 2100–6900
Soybean lipid emulsion 0.0 0.0 0.0 0.0 0.0 0.0 12,000b 23,050 3400–45,000
aUnable to calculate interquartile range due to n = 3.
bDenoting signifant difference (p, 0.05) in median DEHP concentration between fluid without and with DEHP in the IV set using Wilcoxsen ranked sum test.
IV, intravenous; IVF, Intravenous fluid; DEHP, di-2-ethylhexyl phthalate; ND, not dectected; HA, hyperalimentation fluid, IQ, interquartile range. Reproduced from [96] 2021, Toxics.
Table 1. 
DEHP content (mcg/L) in three types of IV fluid, one type of HA fluid, and three types of lipid emulsion.
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early work in animals suggesting that DEHP was a carcinogen, and that it might 
result in injury to male testicular tissue with resultant fertility reduction [7]. These 
problems have not occurred thus far in children.
Cardiac contractility and viability may only be affected by the extreme expo-
sures, such as with cardiac bypass or extracorporeal membrane oxygenation 
circuits [50]. Still, increased blood pressure can be seen with much lower levels 
[2]. Hypertension has been seen with actual and currently occurring DEHP expo-
sures [5]. It is usually seen in patients with substantial postnatal DEHP exposures, 
although the contribution of prenatal phthalate exposures remains unknown, and 
safe levels of postnatal DEHP exposure is unknown.








Conventional intravenous fluid 454 mL 5
Starter (initial) hyperalimentation 133 mL 67
Hyperalimentation fluid 2283 mL 1141
Lipid emulsions 274 mL 2847
Total intravenous DEHP 4039
Mechanical ventilatora 23 days 6616
Bubble CPAP 28 days 219,338
NIPPV 2 days 127
Low flow nasal cannula 1 day 4
High flow cannula 3 days 69
Mean respiratory DEHHP 221,369
Mean IV + respiratory DEHHP 230,207
Mean IV + respiratory DEHHP per Kg 182,369
aUsing non-DEHP endotracheal tube.
All IV tubing was DEHP-positive in these patients. Reproduced from [96] 2021, toxics.
DEHP, Di-2-ethylhexyl phthalate; VLBW, Very low birth weight; IV, Intravenous; CPAP, Continuous positive 
airway pressure; NIPPV, Noninvasive positive pressure ventilation.
Table 3. 
Mean cumulative DEHP exposures for 14 VLBW infants based on actual IV and respiratory exposures using 
above derived values for DEHP exposure for each device.
Respiratory Device n Median (mcg/day) IQ Range (mcg/day)
Bubble CPAP 5 7843.5b 6500.5
Room Air (baseline) 5 25.5 42.5
HFNC 5 21.6 20.3
LFNC 1a 7.3 NA
Ventilator with DEHP-negative ETT 5 61.4 174.1
aFour samples excluded due to additional IVF received by the patient.
bSignifant difference (p < 0.05) in median DEHP exposure between the baseline and other respiratory device using 
Wilcoxsen ranked sum test.
Reproduced from [96] 2021, toxics.
CPAP, continuous positive airway pressure; HFNC, high-flow nasal cannula; IQ, interquartile range; LFNC, 
low-flow nasal cannula; DEHP, di-(2-ethylhexyl phthalate); ETT, endotracheal tube; NA, not able to calculate an 
interquartile range when N = 1.
Table 2. 
Daily DEHP estimated exposures of respiratory therapy device based on urine metabolites of DEHP.
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Liver problems, however, related to actual DEHP exposure were substantiated as 
cholestasis in premature infants was markedly reduced when DEHP IV tubing was 
avoided [68]. In this case, animal studies may also be relevant. Mallow showed daily 
intake of DEHP exposure was 162,459 times that deemed as acceptable by the U.S. 
Consumer Product Safety Commission [12].
The US Environmental Protection Agency (EPA) established an estimate called 
the DEHP reference dose (RfD), as the estimate of safe daily intake of DEHP. This 
was set in 2003 at 20 mcg/kg/day [91]. A Canadian study in 1994 estimated DEHP 
exposure in infants at 9 mcg/kg/day [92]. A more recent study in a subset of the U.S. 
estimated that typical exposure is 0.71 mcg/kg/day [97]. The mean U.S. DEHP level 
associated with this exposure was 2.7 ng/mL [97].
The Consumer Product Safety Improvement Act was passed by the US Congress 
in 2008. This act limited the concentration of six phthalates including DEHP to a 
limit of 0.1% for toys and childcare products [98]. In 2007, the European Union 
effectively banned DEHP from use in medical products [99]. Despite this directive, 
when evaluating European infusion fluid labeled DEHP-free, only two of nine 
devices were indeed DEHP-free [22]. Concern was also raised that the alternative 
phthalate plasticizers have not been fully studied as to risk of adverse effects in 
humans [22, 99].
France, in 2015, banned used of DEHP-containing tubes in neonatal, pediat-
ric, and maternal units [100]. The FDA in the US limits phthalate use in medical 
products to just DEHP. The FDA has not yet set a limit for DEHP, or designated safe 
levels of DEHP use in the US, leaving decisions about use of products containing 
DEHP to providers and hospital administrators. Our experience is this effectively 
leaves the decision up to manufacturers and distributors, as toxicity concerns are 
rarely raised by either hospital staff, providers, or administrators.
6. Actions to reduce DEHP exposures in premature infants
Since premature infants are so small and are still in the midst of develop-
ment it would seem prudent to avoid potential toxicants whenever possible. At 
a minimum, one should strive to reduce neonatal exposure to less than 20 mcg/
day, the estimated safe limit set by the EPA. Lower levels of exposure should be 
achieved if possible. In the past, arguments were made that the benefits of life-
saving medical devices outweigh the unknown and ill-defined risks [9]. Now, 
much of the exposure can be eliminated by choice of products currently available 
by manufacturers.
The easiest step to take would be to not use IV administration sets containing 
DEHP, especially for administration of blood products, hyperalimentation fluid, 
or lipid emulsions. DEHP-free infusion sets are readily available, with little cost 
differential.
The second step would be to use only DEHP-free IV fluid, at least for premature 
infant and maternal use. DEHP-free commercial IV fluid is available in the US 
and abroad.
The third, and potentially the most crucial step would be to limit exposure to 
respiratory devices found to have very large DEHP exposures. We tested only one 
bubble CPAP system, and currently have no data on that from other manufactures 
of bubble CPAP. Advice on CPAP alternatives is beyond the scope of this publica-
tion, but modification of current bubble CPAP, or providing CPAP using either 
a ventilator device or with a linear pressure generator might be preferred from a 
toxicity viewpoint. Specific testing of suspected high-exposure devices may be 
helpful in assessing the risk/benefit ratio for clinical use.




Oregon Health and Sciences University, Portland, Oregon, USA
*Address all correspondence to: jenkinra@ohsu.edu
These changes in medical products should result in marked reductions in DEHP 
exposure, but one has to be vigilant about: 1.) New products that contain DEHP and 
may not be labeled concerning its phthalate content. 2.) Supplies that change on a 
daily basis without providers’ and staff ’s knowledge. This author has seen this occur 
on many occasions. 3) Current products in clinical use which do not have available 
testing data (such as oscillator or jet ventilators).
We suggest periodic checking of IV supplies used in maternal units, and all sup-
plies used in the NICU for products labeled to contain DEHP. It may also be prudent 
to have some system for checking a random patient’s urine for DEHP metabolites, 
as a screen for unexpected DEHP exposure. Lastly, building materials (primarily 
flooring and wall coverings) should be selected to minimize phthalate environmen-
tal exposure in the NICU.
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NICU newborn intensive care unit
MR mineralocorticoid receptor
11β-HSD2 11β-hydroxysteroid dehydrogenase type 2
AME apparent mineralocorticoid excess
MEHP mono-(2-ethylhexyl) phthalate
PRA Plasma renin activity
MEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate
MEOHP mono-(2-ethyl-5-oxohexyl) phthalate
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